Wire · opportunities
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
Eli Lilly presented Phase 1 clinical data for its investigational FRα-targeting antibody-drug conjugate, sofetabart mipitecan combined with bevacizumab, showing a 79% objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer patients, including those pretreated with PARP inhibitors. Sofe-M is being studied in multiple global Phase 3 trials targeting both platinum-sensitive and platinum-resistant ovarian cancer.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clear path to target platinum-sensitive ovarian cancer even after PARP inhibitors fail. The confirmed efficacy across expression levels opens up wider patient access and demands fast integration into your pipeline.
◆ Coverage
1 source · 24 Oct 2026
◆ Related on Wire
◆ Topics